The company also highlighted that bronchiectasis is a chronic, progressive disease with no approved treatments, leaving hundreds of thousands of people in the U.S. without an effective way to reduce ...

Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.

Professor David Denning evaluates timely and accurate diagnosis of Aspergillus infection and the clinical spectrum of ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

The researchers found that the risk for moderate or severe COPD exacerbation was lower among those treated with SGLT-2is versus DPP-4is and among those treated with GLP-1 RAs versus DPP-4is (9.26 ...

Children with asthma whose interferon expression was lower at baseline had shorter time to exacerbation and an increased exacerbation risk during viral illness. Respiratory illnesses that progress to ...

ARINA-1 is under investigation for its ability to increase lung function and decrease exacerbations in NCFB patients. Leading Companies in the Non-Cystic Fibrosis Bronchiectasis (NCFB) Market: The ...

Cefixime is commonly used to treat a variety of bacterial infections, including acute bronchitis, chronic bronchitis exacerbations, bronchiectasis with infection, secondary infections in chronic ...

“Right now, people with bronchiectasis have no approved treatments to prevent pulmonary exacerbations that define this disease and can lead to destruction of lung tissue, putting hundreds of ...

Bronchiectasis affects approximately 450,000 ... to prescribe its drug to patients who had experienced two or more “exacerbations.” Wall Street analysts have speculated that, if approved ...

Insmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its reversible inhibitor of dipeptidyl peptidase 1 (DPP1), brensocatib, for ...